Related Experiment Video
Updated: Jan 3, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.0K
Biosimilars and Novel Insulins.
Francisco Javier Ampudia-Blasco1,2
1Diabetes Reference Unit, Endocrinology and Nutrition Department, Clinic University Hospital Valencia, Valencia, Spain; and.
American Journal of Therapeutics
|November 26, 2019
Summary
Biosimilar insulins offer comparable safety and efficacy to original insulins at a lower cost. Ultrafast-acting insulins like faster aspart show promise for better postprandial glucose control and dosing flexibility.
Area of Science:
- Diabetes management
- Pharmacology
- Biotechnology
Background:
- Insulin therapy is crucial for type 1 and type 2 diabetes.
- Current insulin analogues are effective but costly.
- There is a need for more affordable and faster-acting insulins.
Purpose of the Study:
- To review the efficacy, safety, and cost-effectiveness of biosimilar insulins.
- To evaluate the potential of ultrafast-acting insulins for improved glycemic control.
Main Methods:
- Systematic review of relevant literature.
- Searches conducted in Medline, Embase, Cochrane Library, and SCISEARCH.
Main Results:
- Biosimilar insulins (e.g., LY2963016, MK-1293, SAR342434) demonstrate comparable efficacy and safety to originators.
- Faster-acting insulin aspart shows noninferiority in HbA1c reduction and superiority in postprandial control.
- Interchangeability and automatic substitution of biosimilar insulins remain unresolved issues.
Conclusions:
- Biosimilar insulins provide a cost-effective alternative with equivalent clinical profiles.
- Faster aspart represents a significant advancement in ultrafast-acting insulin formulations.
- Further clinical trials and experience are needed to fully establish the potential of faster aspart.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
204
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
204
01:27Insulin Formulations: Types and Delivery
584
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
584
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.1K
01:24Glucagon-like Receptor Agonists
790
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
790
01:06Oral Hypoglycemic Agents: Glinides
538
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
538
01:17Oral Hypoglycemic Agents: Sulfonylureas
685
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
685